Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 12/20 | 0.47 |
| ▸ | KDR | P35968 | 8/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931060 | 1.00 | AURKA (0.48) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL3926784 | 0.89 | AURKA (0.49) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL3924607 | 0.89 | AURKA (0.49) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL3924602 | 0.87 | AURKA (0.48) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL3924605 | 0.87 | AURKA (0.48) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL3931206 | 0.83 | AURKA (0.49) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL3931210 | 0.83 | AURKA (0.49) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL27681187 | 0.81 | AURKA (0.54) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL3931064 | 0.79 | AURKA (0.46) | AURKAAURKBCHEK1KDRFGFR1 | |
| SCHEMBL27681104 | 0.78 | KDR (0.52) | AURKAAURKBCHEK1KDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | claimed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | claimed |
| EP-1732938-B1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | disclosed |
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| EP-1732938-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005058923-A1 | ORGANOPHOSPHOROUS INDAZOLE DERIVATIVES AND USE THEREOF AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2005-06-30 | — | — | WO | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | AURKA 553/4885AURKB 597/4885CHEK1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.